We are proud to share that IFG, in collaboration with our partner Ovogene Bank, presented scientific research at FSANZ 2026, one of the leading fertility congresses in the Asia−Pacific region! Organized under the Fertility Society of Australia and New Zealand, this event brings together reproductive health professionals from around the world to exchange research, clinical experience, and best practices in assisted reproductive technology (ART).
For IFG, taking part in international congresses like FSANZ is an essential part of how we operate. As a global fertility management agency coordinating IVF, surrogacy, egg donation, and Mitochondrial Replacement Therapy (MRT) programs across our network of accredited clinics in Ukraine, Albania, Georgia, Slovakia, Mexico, Armenia, and the United States, we believe our patients deserve care rooted in the latest science.
Our Scientific Poster
The research presented at FSANZ 2026 was titled Intraovarian Use of Adipose−Derived Stem Cells in Poor Responders: Transient Endocrine Changes and Follicular Recruitment. The work was featured within the congress's broader scientific track dedicated to the safety and quality of ART therapies, including clinical guidelines, accreditation, treatment complications, and long−term outcomes.
The poster examined how adipose−derived stem cell therapy may influence hormonal activity and follicular development in poor responders, patients whose ovaries typically produce fewer eggs during stimulation. Findings like these contribute to a growing body of evidence exploring new avenues for patients who haven't had success with conventional protocols, and reflect the kind of forward−looking clinical research that shapes better outcomes across the fertility field.
A Commitment to Global Reproductive Medicine
As a U.S.−based agency operating at the intersection of medicine and personalized patient management, IFG sees international congresses as more than an opportunity to share findings; they're where the future of fertility care gets shaped. By engaging directly with embryologists, clinicians, and researchers from around the world, we ensure that the protocols used across our partner network stay aligned with the most current, evidence−based standards in reproductive medicine.
Presenting at FSANZ 2026 reaffirms our ongoing commitment to bridging medical excellence with compassionate, transparent care — the same principle that guides every family we support, from first consultation to the moment they hold their baby.
We're proud to represent our teams on the international stage and look forward to continuing this important work at future conferences around the world. See you at the next one!
Want to learn more about IFG's fertility programs? Get in touch with our team to start your journey.
